{"nctId":"NCT00478231","briefTitle":"Multicenter, Safety Study Of Maraviroc","startDateStruct":{"date":"2007-07"},"conditions":["Acquired Immunodeficiency Syndrome","HIV Infection"],"count":209,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Maraviroc"]}],"interventions":[{"name":"Maraviroc","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with limited or no approved treatment options available to them due to resistance or intolerance;\n* Subjects must be failing to achieve adequate virologic suppression on their current regimen and have HIV-1 RNA â‰¥ 1000 copies/ml, at screening.\n* Have only R5 HIV-1 at Screening as verified by the Monogram Biosciences Trofile assay.\n\nExclusion Criteria:\n\n* Failed prior treatment with any CCR5 antagonist, in any ongoing CCR5 trials or having previously discontinued Maraviroc in trials\n* Potentially life threatening (Grade 4) laboratory abnormality or medical condition (according to the Division of AIDS table for grading severity of adult adverse experiences) still under investigation unless a diagnosis has been established and felt not to affect risk/benefit assessment or eventual interpretation of safety results, based on discussion between the investigator and Pfizer.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Grade 3 and Grade 4 Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":"AEs: any untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was congenital anomaly. Grade 3: Events that interrupted participant's usual daily activity and traditionally required systemic drug therapy or other treatment. Grade 4: Events which were unacceptable and intolerable or which were irreversible or caused participant to be in imminent danger of death.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 and Grade 4 Laboratory Abnormalities","description":"Grade 3 or severe events included those that interrupted participant's usual daily activity and traditionally required systemic drug therapy or other treatment. Grade 4 or very severe events included those that were unacceptable and intolerable or which were irreversible or caused the participant to be in imminent danger of death.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Treatment Emergent Malignancies","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Category C Acquired Immunodeficiency Syndrome (AIDS) Related Infections","description":"Number of participants with AIDS-related infections based on investigator classification guided by a predefined list of clinical Category C AEs per Center for Disease Control (CDC) HIV Classification System.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Laboratory Test Abnormalities","description":"Pre-defined criteria based on upper limit normal (ULN) and lower limit normal (LLN) were established for each laboratory test to define the values that would be identified as laboratory test abnormality.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"115","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"101","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"145","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With at Least 0.5 Log 10 Reduction in Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With at Least 1.0 Log 10 Reduction in HIV-1 RNA","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving HIV-1 RNA Below Limit of Quantification","description":"Below limit of quantification was defined as less than 400 copies/milliliter (mL)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Lymphocyte Cluster of Differentiation 4 (CD4) Count at Week 4, 8, 12, 24, 36, 48, 60, 72, 84 and Week 96 or EOT","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"215.6","spread":"179.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.5","spread":"96.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"110.0","spread":"95.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"132.1","spread":"164.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"137.3","spread":"115.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"157.8","spread":"128.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"172.2","spread":"124.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"187.2","spread":"140.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"199.8","spread":"161.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"198.2","spread":"177.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"225.2","spread":"175.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"174.1","spread":"168.5"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Lymphocyte Cluster of Differentiation 8 (CD8) Count at Week 4, 8, 12, 24, 36, 48, 60, 72, 84 and Week 96 or EOT","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1016.4","spread":"676.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"387.3","spread":"597.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"518.3","spread":"666.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"507.2","spread":"685.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"358.1","spread":"577.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"352.3","spread":"545.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"348.6","spread":"591.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"349.1","spread":"566.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"272.4","spread":"594.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"246.7","spread":"567.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"214.5","spread":"593.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"223.0","spread":"562.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Percent at Week 4, 8, 12, 24, 36, 48, 60, 72, 84 and Week 96 or EOT","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.2","spread":"7.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"3.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"3.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"4.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"3.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"3.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":"4.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":"4.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":"4.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":"5.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"5.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":"5.3"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD8 Percent at Week 4, 8, 12, 24, 36, 48, 60, 72, 84 and Week 96 or EOT","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.8","spread":"13.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"6.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"7.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"8.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"8.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.6","spread":"8.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.3","spread":"9.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.7","spread":"10.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.1","spread":"10.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.8","spread":"10.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.7","spread":"10.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.4","spread":"10.6"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With C-X-C Chemokine Receptor Type 4 {CXCR4} [X4] Tropism Status","description":"Virus tropism was done by the Monogram Biosciences Trofile assay.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in Human Immunodeficiency Virus (HIV) -1 Viral Load (Ribonucleic Acid [RNA]) at Week 4, 8, 12, 24, 36, 48, 60, 72, 84 and Week 96 or EOT","description":"Change from baseline in log 10-transformed plasma viral load (HIV-1 RNA) levels (log 10 copies per milliliter \\[log10 copies/ml\\]).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":"0.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"1.1"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Time to Virologic Failure (VF)","description":"Virologic failure was defined as failing to achieve a reduction in HIV-1 RNA of at least 0.5 log10 copies/ml from baseline by the second viral load determination; or experiencing at least 0.5 log10 increase from nadir in HIV-1 RNA after achieving an HIV-1 RNA reduction from baseline more than 0.5 log10 copies/ml; or experiencing an HIV-1 RNA more than 1000 copies/ml after having achieved an HIV-1 RNA below level of quantification.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"255.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Genotype Resistance","description":"Evolution in resistance to OBT was shown by emergence of new primary or secondary resistance mutations to nucleoside reverse transcriptase inhibitor (NRTI), non-nucleoside reverse transcriptase inhibitor (NNRTI) and protease inhibitor (PI).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":34,"n":206},"commonTop":["Diarrhoea","Nasopharyngitis","Headache","Subcutaneous nodule","Sinusitis"]}}}